血霁生物

Xueji Biotech is a pioneering Chinese biotechnology company focused on the industrial-scale production of platelets using induced pluripotent stem cell (iPSC) technology. The company's proprietary platform enables the differentiation of iPSCs into megakaryocytes and subsequently into functional platelets, providing a sustainable alternative to traditional blood donor-dependent transfusions. Their primary therapeutic focus is treating thrombocytopenia, but the platform also extends to engineered platelets for targeted drug delivery in oncology and regenerative medicine applications. Founded in 2021 and headquartered in Suzhou's BioBAY, Xueji Biotech has secured significant backing from top-tier investors like Hillhouse and Matrix Partners China. The company aims to solve the global clinical shortage of platelets through innovative cell manufacturing and synthetic biology.